Management of gout: beyond allopurinol. - Wikidata - awgldk - TriplyDB

Management of gout: beyond allopurinol.

Management of gout: beyond allopurinol.

http://www.wikidata.org/entity/Q37766274

about

Biosensors Incorporating Bimetallic Nanoparticles.Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice.

P2860

Q29248731-357AB88E-552F-449B-BC48-4DD95623E206 Q35570950-46EFFE62-5633-4927-84C2-E32FB2F87BBC

P2860

Management of gout: beyond allopurinol.

http://www.wikidata.org/entity/Q37766274

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 June 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Management of gout: beyond allopurinol.

@en

Management of gout: beyond allopurinol.

@nl

type

label

Management of gout: beyond allopurinol.

@en

Management of gout: beyond allopurinol.

@nl

prefLabel

Management of gout: beyond allopurinol.

@en

Management of gout: beyond allopurinol.

@nl

P1433

Q37766274-7689C6B6-635D-404F-B683-175D4C9CBDCA

P1476

Q37766274-82FB6D16-55FB-4239-9E4C-693400DE2947

P2093

Q37766274-0D2D0BAB-2ED0-42EF-BB99-246D66B74757

P2860

Q37766274-01B087C7-0BF8-47EA-8394-4855D20AEE9D

Q37766274-03ECD03C-84F2-433B-88FF-41BA1EA321DF

Q37766274-0878D457-4018-4BA6-8F0B-6556233BBC60

Q37766274-113F1A71-F7FF-413C-8D09-E95D192390C8

Q37766274-117F83A5-C17C-498D-9B2D-4D2618AA4429

Q37766274-1FB75C8C-80F9-43CB-A07E-18537D7ABB1E

Q37766274-23256312-34BB-4C88-9EBB-1916D8086EE3

Q37766274-28F673C4-0C6C-4886-8E54-9712C65EB620

Q37766274-3A4B67CE-A8DF-40E0-8A55-0483E32E140E

Q37766274-3FB4D615-76B6-4EC8-8A90-5278183B9F89

P304

Q37766274-476F4F7F-4572-4DCE-BD7F-86342DD4DBAE

P31

Q37766274-FDE1C6BD-15D2-4F87-8529-994849CEDB82

P356

Q37766274-702D22DD-5B3B-444C-BB32-1432A88427F9

P433

Q37766274-6CD18682-D8E7-43ED-9C2C-848AED0EACBA

P478

Q37766274-9C41936D-BCAA-496C-97AC-0209C9A28A2B

P577

Q37766274-DA9CE02B-6B02-4300-B320-C4566CB7808C

P698

Q37766274-556C8938-BD2C-4C4F-9E2A-74C5EB22102F

P356

J.1445-5994.2010.02293.X

P1433

Internal Medicine Journal

P1476

Management of gout: beyond allopurinol.

@en

P2093

N W McGill

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology of gout

Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study

Vitamin C intake and the risk of gout in men: a prospective study

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout

Relation between adverse events associated with allopurinol and renal function in patients with gout

Allopurinol treatment and its effect on renal function in gout: a controlled study

Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

P304

545-553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1445-5994.2010.02293.X

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20561096

http://www.w3.org/2001/XMLSchema#string